Literature DB >> 26673510

Refractory Peristomal Pyoderma Gangrenosum Successfully Treated With Intravenous Immunoglobulin: A Case Report.

Brian P McAllister1, Emmanuelle D Williams2, Lisa J Yoo2, Andrew Tinsley2, Walter Koltun3, Christine M Ardell3, Suzi B Follett4, Diane M Paskey4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26673510     DOI： 10.1038/ajg.2015.344

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Intravenous immunoglobulin for pyoderma gangrenosum.

Authors:  A Kreuter; S Reich-Schupke; M Stücker; P Altmeyer; T Gambichler
Journal:  Br J Dermatol       Date:  2008-01-30       Impact factor: 9.302

Review 2.  Intravenous immunoglobulin for the treatment of Crohn's disease.

Authors:  Moshe Rogosnitzky; Rachel Danks; Daniel Holt
Journal:  Autoimmun Rev       Date:  2012-05-08       Impact factor: 9.754

3.  Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene.

Authors:  Zhenwu Lin; John P Hegarty; Tony Lin; Barbara Ostrov; Yunhua Wang; Wei Yu; Ashley A Kelly; Lisa S Poritz; Walter A Koltun
Journal:  Inflamm Bowel Dis       Date:  2011-03-15       Impact factor: 5.325

Review 4.  Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria.

Authors:  Angelo V Marzano; Rim S Ishak; Simone Saibeni; Carlo Crosti; Pier Luigi Meroni; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 5.  Treatment of pyoderma gangrenosum with intravenous immunoglobulin.

Authors:  D L Cummins; G J Anhalt; T Monahan; J H Meyerle
Journal:  Br J Dermatol       Date:  2007-10-04       Impact factor: 9.302
  5 in total
  1 in total

1.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.